Carlsmed (NASDAQ:CARL) Stock: Insider Jeffrey Bertolini Sells 747 Shares

Key Points

• Carlsmed COO Jeffrey Bertolini sold 747 shares at an average price of $15.15, for about $11,317; he retained 22,489 shares after the sale.
• Carlsmed shares rose 12.2% to $16.15 in Wednesday trading, with a 52-week range of $8.50 to $17.23.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $19.50. The company’s latest reported quarterly loss was $0.39 per share, slightly better than estimates.

Carlsmed, Inc. (NASDAQ:CARL - Get Free Report) COO Jeffrey Bertolini sold 747 shares of the business's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $15.15, for a total transaction of $11,317.05. Following the sale, the chief operating officer directly owned 22,489 shares of the company's stock, valued at $340,708.35. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jeffrey Bertolini also recently made the following trade(s):

• On Friday, October 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The stock was sold at an average price of $15.80, for a total transaction of $3,839.40.
• On Monday, October 5th, Jeffrey Bertolini sold 747 shares of Carlsmed stock. The stock was sold at an average price of $14.39, for a total transaction of $10,749.33.
• On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $13.99, for a total transaction of $3,399.57.

Carlsmed Trading Up 12.2%

CARL traded up $1.75 on Wednesday, reaching $16.15. 90,824 shares of the company traded hands, compared to its average volume of 132,142. The company has a market cap of $440.89 million, a P/E ratio of -11.29 and a beta of 1.97. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. Carlsmed, Inc. has a one year low of $8.50 and a one year high of $17.23. The firm has a fifty day simple moving average of $14.98 and a two-hundred day simple moving average of $12.46.

Carlsmed (NASDAQ:CARL - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. The business had revenue of $18.94 million for the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. As a group, equities research analysts expect that Carlsmed, Inc. will post -1.50 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CARL shares. BTIG Research increased their price objective on Carlsmed from $23.00 to $24.00 and gave the stock a "buy" rating in a research note on Monday, October 12th. Wall Street Zen upgraded Carlsmed from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Weiss Ratings upgraded Carlsmed from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, Truist Financial increased their price target on Carlsmed from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Carlsmed has an average rating of "Moderate Buy" and an average price target of $19.50.

Institutional Investors Weigh In On Carlsmed

Several large investors have recently modified their holdings of the business. Zevenbergen Capital Investments LLC increased its holdings in Carlsmed by 50.4% during the third quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company's stock valued at $252,000 after buying an additional 6,000 shares during the period. Bank of America Corp DE purchased a new stake in Carlsmed during the second quarter worth $108,000. Jupiter Topco LLC purchased a new stake in Carlsmed during the second quarter worth $12,992,000. Parkman Healthcare Partners LLC purchased a new stake in Carlsmed during the second quarter worth $6,200,000. Finally, Alpine Woods Capital Investors LLC bought a new stake in Carlsmed during the 2nd quarter valued at $161,000.

Carlsmed Company Profile

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed's technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.